Apidra, a rapid-acting insulin, received its initial U.S. approval in 2004 [1]. It is used to control high blood sugar in adults and children with diabetes mellitus [2].
How does Apidra work?
Apidra is a synthetic analog of human insulin [3]. It works by lowering blood glucose levels by increasing the rate at which glucose is taken up by peripheral tissues and by inhibiting glucose production in the liver [2]. It begins to work rapidly, typically within 15 minutes, and its effect lasts for 2 to 4 hours [2].
When does Apidra's patent protection expire?
The patent protection for Apidra has expired, allowing for the development and introduction of biosimilar alternatives. Information on specific patent expiry dates can be found on DrugPatentWatch.com [4].
What are the alternatives to Apidra?
Several other rapid-acting insulin analogs are available for diabetes management, including Humalog (insulin lispro) and Novolog (insulin aspart) [5]. These insulins share similar mechanisms of action and are used to manage blood glucose levels around meal times [5].
What is the cost of Apidra?
The cost of Apidra can vary depending on insurance coverage, pharmacy, and dosage. Patients often seek out information on Apidra pricing and potential savings programs to manage out-of-pocket expenses [6].
Are there generic or biosimilar versions of Apidra?
With the expiry of its patents, biosimilar versions of Apidra are now available. These biosimilars offer alternative treatment options for patients and can impact market competition and drug pricing [4].
What are the risks and side effects associated with Apidra?
Like all insulins, the most common side effect of Apidra is hypoglycemia, or low blood sugar [2]. Other potential side effects include injection site reactions, lipodystrophy, and allergic reactions [2]. Patients are advised to monitor for symptoms of low blood sugar and discuss any concerns with their healthcare provider [2].
How does Apidra compare to other insulins?
Apidra's onset of action is similar to other rapid-acting insulins like Humalog and Novolog, making it suitable for mealtime insulin therapy. However, individual responses to different insulin formulations can vary [2, 5].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/apidra-insulin-human-injection-safety-labeling-changes
[2] https://www.drugs.com/apidra.html
[3] https://www.rxlist.com/apidra-drug.htm
[4] https://drugpatentwatch.com/
[5] https://www.nps.org.au/australian-medicines-australia/insulins-and-their-use-in-diabetes
[6] https://www.goodrx.com/apidra